- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT07624448
Regulating Together for Intellectual Disability and Autism: A Group Behavioral Therapy for for Emotion Dysregulation (RT-ID)
Adapting a Group Intervention for Emotion Dysregulation in Autism and Intellectual Disability
The goal of this study is to help children with autism and a co-occurring intellectual disability and their families learn practical strategies for managing issues like irritability, aggression, and other challenging behaviors. The main objective of this study is:
To adapt current Regulating Together materials to create an outpatient group program for emotion dysregulation in autism and co-occurring intellectual disability (ASD + ID) that will improve psychosocial outcomes for youth with ASD + ID.
Přehled studie
Postavení
Intervence / Léčba
Detailní popis
Up to ten children with autism and co-occurring Intellectual Disability (ASD + ID) ages 8 to 12 years and their caregivers will be enrolled in the study. This study is being done to develop and test a behavior therapy to help children with ASD + ID calm their emotions. Participants will complete assessments at five time points:
Screening (T1); Week 0: Baseline visit (T2); Week 5: Post Active Treatment (T3); Week 10: 5 week follow-up (T4); and Week 15: 10 week follow-up (T5). Participants will receive 5 weeks of intervention, twice per week, following the T2 visit.
Typ studie
Zápis (Odhadovaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
- Jméno: Grayson Manley, RN
- Telefonní číslo: 816-816-6967
- E-mail: gmanley@cmh.edu
Studijní místa
-
-
Missouri
-
Kansas City, Missouri, Spojené státy, 64108
- Nábor
- Children's Mercy
-
Kontakt:
- Grayson Manley, RN
- Telefonní číslo: 816-816-6967
- E-mail: gmanley@cmh.edu
-
Vrchní vyšetřovatel:
- Walker McKinney, PhD
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
- Dítě
Přijímá zdravé dobrovolníky
Popis
Child Participant Inclusion Criteria:
- Males, females, or non-binary youth between 8 and 12 years of age
- Confirmed diagnosis of Autism Spectrum Disorder (ASD)
- Confirmed diagnosis of Intellectual Disability
- Fluent in spoken English.
- Use of flexible phrase speech or greater
- Meeting clinically significant emotion dysregulation criteria
- Willing to participate in twice weekly 90-minute sessions
- Family is willing to keep prescribed psychiatric medication and outside behavioral interventions stable
- Parent, guardian, or legally authorized representative (LAR) must provide written permission on behalf of the participant
Child Participant Exclusion Criteria:
- Initiation of new psychosocial intervention within 30 days prior to first day of treatment
- Presence of physical aggression in the child directed towards a peer outside the home (i.e., non-siblings) that resulted in injury within 30 days prior to screening. Other significant disruptive, aggressive, self-injurious, or sexually inappropriate behavior felt to be dangerous or overly disruptive to the group sessions will be reviewed by the study team on an individual basis.
- Presence of comorbid major neuropsychiatric illness warranting other treatment approaches
- Presence of any major sensory impairment that would limit participating in the material including blindness or uncorrected hearing loss
Caregiver Inclusion Criteria:
- Age ≥ 18 years
- Lives and cares for their child with ASD+ID for > 50% of the year
- Fluent in spoken English.
- Willing to participate in twice weekly 90-minute sessions, including one virtual session weekly
Caregiver Exclusion Criteria:
-Presence of any major sensory impairment that would limit participating in the material including blindness or uncorrected hearing loss
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Children with autism and co-occurring intellectual disability and their caregiver
Participants will receive Regulating Together - the emotion dysregulation intervention
|
Regulating Together is the original curriculum developed for autistic youth that uses evidence-based therapeutic strategies including relaxation techniques, parent management training, and mindfulness to help regulate emotions.
This study will adapt the original Regulating Together curriculum to focus on behavioral interventions to treat emotion dysregulation in Autism with a co-occurring intellectual disability.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Emotion Dysregulation Inventory - Reactivity
Časové okno: From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
The Emotion Dysregulation Inventory consists of two subscales.
The investigators will use the Reactivity subscale which captures poorly regulated negative emotional responses and a dysphoria subscale characterized by increased negative affect and lack of motivation.
Minimum raw score: 0; Maximum raw score: 96; Higher scores reflect higher emotional reactivity.
|
From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Clinician Global Impressions - Improvement (CGI-I)
Časové okno: From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
A trained, independent clinician will rate the CGI at T3 and T5.
The CGI-I provides a qualitative measure of treatment response through a rating from 1=very much improved to 7=very much worse.
|
From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
|
Emotion Regulation Skills Test
Časové okno: From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
A child self-report measure created for Regulating Together to measure knowledge of skills taught to manage emotion dysregulation.
|
From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
|
Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety and Depression Scales (Parent-Proxy)
Časové okno: From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
Caregiver-report measures to measure change in internalizing symptoms.
For both measures: minimum raw value: 13; maximum raw value: 65; higher scores reflect greater anxiety/depression
|
From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
|
Aberrant Behavior Checklist, 2nd Edition (ABC-2)
Časové okno: From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
Irritability subscale; a caregiver-report measures to measure change in irritability and related challenging behaviors.
Minimum score: 0; Maximum score: 45; higher scores reflect greater irritability
|
From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
|
Parenting Stress Index, 4th Edition, Short Form
Časové okno: From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
A caregiver-report questionnaire measuring the magnitude of stress in the parent-child system.
Minimum score: 36; Maximum score: 180; Higher scores reflect greater parental stress
|
From enrollment to the end of their follow up appointment, about 10 weeks after therapy has completed
|
|
Caregiver and Child Readiness and Satisfaction Surveys
Časové okno: From enrollment to end of follow up at 15 weeks
|
The investigators will assess acceptability as reflected in the average caregiver and child satisfaction rating measured using two study-specific measures.
Caregivers will complete the Caregiver Readiness and Satisfaction Survey and children will complete the Child Readiness and Satisfaction Survey.
|
From enrollment to end of follow up at 15 weeks
|
Spolupracovníci a vyšetřovatelé
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Walker McKinney, PhD, Children's Mercy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
- Poruchou autistického spektra
- Aberantní motorické chování u demence
- Neurologické projevy
- Nemoci nervového systému
- Duševní poruchy
- Symptomy chování
- Neurobehaviorální projevy
- Neurologické vývojové poruchy
- Poruchy vývoje dítěte, všudypřítomné
- Patologické stavy, příznaky a symptomy
- Chování
- Příznaky a symptomy
- Společenské chování
- Autistická porucha
- Intelektuální postižení
- Agrese
Další identifikační čísla studie
- STUDY00004069
- KL2TR002367 (Grant/smlouva NIH USA)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Intelektuální postižení
-
Unravel Biosciences, Inc.Nábor
-
Georgetown UniversityCharite University, Berlin, Germany; Fraunhofer Heinrich Hertz Institut (HHI); Max-Planck-Institute for Cognition a další spolupracovníciAktivní, ne náborRettův syndromSpojené státy
-
University of RochesterNáborRettův syndromSpojené státy
-
UCB BIOSCIENCES, Inc.Zatím nenabírámeRettův syndromSpojené státy, Maďarsko, Japonsko
-
Mirum Pharmaceuticals, Inc.Nábor
-
SpinogenixZatím nenabírámeSyndrom křehkého X (FXS)
-
Taysha Gene Therapies, Inc.Nábor
-
Fenix Innovation GroupNeurotech International LimitedZatím nenabírámeRettův syndrom | RETT syndrom s prokázanou mutací MECP2Austrálie
-
University of California, San FranciscoNáborEpileptická encefalopatie, začátek v dětství | Vývojová dysfázie | X-Linked Intellectual DisabilitySpojené státy
-
Rett Syndrome Research TrustNáborRettův syndromSpojené státy